Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is open-label, single-arm, two-stage phase II trial of olaparib in patients with
relapsed/refractory metastatic germ cell cancer. The primary objective is to evaluate the
preliminary activity of Olaparib in GCT tumors. The secondary objective is to evaluate the
safety of Olaparib in patients with cisplatin-refractory GCT.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori